Page last updated: 2024-11-12

miv 150

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MIV 150: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9907284
CHEMBL ID391735
SCHEMBL ID3732549
MeSH IDM0498051

Synonyms (24)

Synonym
miv-150
CHEMBL391735 ,
1-(5-cyano-2-pyridyl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoyl-phenyl)cyclopropyl]urea
miv150
urea, n-[(1s,2s)-2-[6-fluoro-2-hydroxy-3-(1-oxopropyl)phenyl]cyclopropyl]-n'-(5-cyano2-pyridinyl)-
824vsi942y ,
pc 815
231957-54-3
miv 150
1-(5-cyanopyridin-2-yl)-3-((1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl)urea
unii-824vsi942y
SCHEMBL3732549
pc-815
urea, n-(5-cyano-2-pyridinyl)-n'-((1s,2s)-2-(6-fluoro-2-hydroxy-3-(1-oxopropyl)phenyl)cyclopropyl)-
pc-1005 component miv-150
miv-150 component of pc-1005
DTXSID70177773
bdbm50477159
CS-0015478
HY-19378
miv-1r
Q27269302
1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea
AKOS040742143

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse events, which were primarily mild and/or unrelated, were comparable between groups."( First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.
Alami, M; Creasy, GW; Fernández-Romero, JA; Friedland, BA; Hoesley, CJ; Hoskin, E; Katzen, LL; Kleinbeck, KR; Novak, L; Plagianos, M; Teleshova, N; Zhang, S; Zydowsky, TM, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters were calculated using noncompartmental techniques and actual sampling times."( First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.
Alami, M; Creasy, GW; Fernández-Romero, JA; Friedland, BA; Hoesley, CJ; Hoskin, E; Katzen, LL; Kleinbeck, KR; Novak, L; Plagianos, M; Teleshova, N; Zhang, S; Zydowsky, TM, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" CVL antiviral EC50 values were calculated using a dose-response inhibition analysis."( First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.
Alami, M; Creasy, GW; Fernández-Romero, JA; Friedland, BA; Hoesley, CJ; Hoskin, E; Katzen, LL; Kleinbeck, KR; Novak, L; Plagianos, M; Teleshova, N; Zhang, S; Zydowsky, TM, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Kd0.00200.00062.40599.8000AID301920; AID301921; AID301922; AID301923; AID301924; AID301925; AID301926; AID301927
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID301922Binding affinity to HIV1 reverse transcriptase K103N mutant at 25 degC2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301921Binding affinity to HIV1 reverse transcriptase K103N mutant at 15 degC2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301920Binding affinity to HIV1 reverse transcriptase K103N mutant at 5 degC2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301926Binding affinity to HIV1 reverse transcriptase Y181C mutant at 25 degC2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301923Binding affinity to HIV1 reverse transcriptase K103N mutant at 35 degC2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301924Binding affinity to HIV1 reverse transcriptase Y181C mutant at 5 degC2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301927Binding affinity to HIV1 reverse transcriptase Y181C mutant at 35 degC2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301925Binding affinity to HIV1 reverse transcriptase Y181C mutant at 15 degC2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (16.67)29.6817
2010's19 (79.17)24.3611
2020's1 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.10 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (8.33%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]